NA 015
Alternative Names: NA-015Latest Information Update: 08 Sep 2023
At a glance
- Originator Nanomerics
- Developer Nanomerics; Virpax Pharmaceuticals
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 29 Jun 2023 Phase-I clinical trials in COVID-2019 infections in United Kingdom (unspecified route), prior to June 2023 (Nanomerics pipeline, June 2023)
- 29 Jun 2023 Preclinical trials in COVID-2019 infections in United Kingdom (unspecified route), prior to June 2023 (Nanomerics pipeline, June 2023)